Clinical applications of DNA microarray analysis

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 6, 2003, Pages 297-304

  Dudda Subramanya, Raghunandan ^a   Lucchese, Guglielmo ^b   Kanduc, Darja ^b   Sinha, Animesh A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

DNA microarray; Gene chip; Genome profiling

Indexed keywords

ALPHA INTERFERON; ANNEXIN; BUTHIONINE SULFOXIMINE; CALPASTATIN; CD19 ANTIGEN; CD34 ANTIGEN; CERAMIDE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; CREATINE KINASE BB; DNA; GLUTATHIONE; IMATINIB; IMMUNOMODULATING AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MELPHALAN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; STI 561; UNCLASSIFIED DRUG;

BIOINFORMATICS; CLINICAL OBSERVATION; DISEASE CLASSIFICATION; DNA DETERMINATION; DNA FINGERPRINTING; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; HUMAN; HYPOTHESIS; MOLECULAR BIOLOGY; NONHUMAN; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW;

GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 0346727380     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1533-869X.2003.01104.x     Document Type: Review

References (45)

1. Arcellana-Panlilio M, Robbins SM. Cutting-edge technology. I. Global gene expression profiling using DNA microarrays. Am J Physiol Gastrointest Liver Physiol 282: G397-G402, 2002.
2. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 286: 2280-2288, 2001.
3. Jordan B. Historical background and anticipated developments. Ann NY Acad Sci 975: 24-32, 2002.
4. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470, 1995.
5. Hacia JG. Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet 21: 42-47, 1999.
6. Barrett JC, Kawasaki ES. Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. Drug Discov Today 8: 134-141, 2003.
7. Liefers GJ, Tollenaar RA. Cancer genetics and their application to individualised medicine. Eur J Cancer 38: 872-879, 2002.
8. Okutsu J, Tsunoda T, Kaneta Y, et al. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther 1: 1035-1042, 2002.
9. Slonim DK. From patterns to pathways: gene expression data analysis comes of age. Nat Genet 32: 502-508, 2002.
10. Bijlani R, Cheng Y, Pearce DA, et al. Prediction of biologically significant components from microarray data: independently consistent expression discriminator (ICED). Bioinformatics 19: 62-70, 2003.
11. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33: 90-96, 2003.
12. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
13. Bicciato S, Pandin M, Didone G, et al. Pattern identification and classification in gene expression data using an autoassociative neural network model. Biotechnol Bioeng 81: 594-606, 2003.
14. Chu LW, Troncoso P, Johnston DA, et al. Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 36: 303-312, 2003.
15. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764, 1999.
16. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61: 6185-6193, 2001.
17. Wang H, Maurer BJ, Reynolds CP, et al. N-(4-hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 61: 5102-5105, 2001.
18. Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 30: 135-140, 2002.
19. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101: 1718-1726, 2003.
20. Pertl U, Wodrich H, Ruehlmann JM, et al. Immunotherapy with a post-transcriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101: 649-654, 2003.
21. Legault J, Gaulin JF, Mounetou E, et al. Microtubule disruption induced in vivo by alkylation of beta-tubulin by 1-aryl-3-(2-chloroethyl) ureas, a novel class of soft alkylating agents. Cancer Res 60: 985-992, 2000.
22. Kudoh K, Ramanna M, Ravatn R, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60: 4161-4166, 2000.
23. Kihara C, Tsunoda T, Tanaka T, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 61: 6474-6479, 2001.
24. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497, 1960.
25. Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95: 738-743, 2000.
26. Thomas ED, Clift A, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155-163, 1986.
27. Cortes J, Kantarjian HM, Giralt S, et al. Natural history and staging of chronic myelogenous leukemia. Baillieres Clin Haematol 10: 277-290, 1997.
28. Radich JP, Gooley T, Bryant E, et al. The significance of BCR-ABL molecular detection in chronic myeloid leukemia patients "late", 18 months or more after transplantation. Blood 98: 1701-1707, 2001.
29. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomized, multicentre trial of interferon-α for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet 345: 1392-1397, 1995.
30. Cohen N, Rozenfeld-Granot G, Hardan I, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128: 114-119, 2001.
31. Lauta VM. Interferon and chronic myelogenous leukemia. Med Oncol 12: 41-46, 1995.
32. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 9: 160-166, 2003.
33. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98: 9754-9759, 2001.
34. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 14: 783-785, 2000.
35. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 339: 605-615, 1998.
36. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85: 1416-1434, 1995.
37. Chen X, Pan Q, Stow P, et al. Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay. Leukemia 15: 166-170, 2001.
38. Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 16: 3774-3781, 1998.
39. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352: 1731-1738, 1998.
40. Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 97: 2115-2120, 2001.
41. Sarwal M, Chang S, Barry C, et al. Genomic analysis of renal allograft dysfunction using cDNA microarrays. Transplant Proc 33: 297-298, 2001.
42. Akalin E, Hendrix RC, Polavarapu RG, et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 72: 948-953, 2001.
43. Hwang JJ, Allen PD, Tseng GC, et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 10: 31-44, 2002.
44. Zhang S, Day IN, Ye S. Microarray analysis of nicotine-induced changes in gene expression in endothelial cells. Physiol Genomics 5: 187-192, 2001.
45. Mandel S, Grunblatt E, Maor G, et al. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res 27: 1231-1243, 2002.